[1] KOSTYUNIN A, MUKHAMADIYAROV R, GLUSHKOVA T, et al. Ultrastructural Pathology of Atherosclerosis, Calcific Aortic Valve Disease, and Bioprosthetic Heart Valve Degeneration: Commonalities and Differences. Int J Mol Sci. 2020;21(20):7434.
[2] YANG Y, WANG Z, CHEN Z, et al. Current status and etiology of valvular heart disease in China: a population-based survey. BMC Cardiovasc Disord. 2021;21(1):339.
[3] HARKEN DE, SOROFF HS, TAYLOR WJ, et al. Partial and complete prostheses in aortic insufficiency. J Thorac Cardiovasc Surg, 1960;40(6): 744-762.
[4] FATIMA B, MOHANANEY D, KHAN F W, et al. Durability Data for Bioprosthetic Surgical Aortic Valve: A Systematic Review. JAMA Cardiol, 2019;4(1):71-80.
[5] SOMERVILLE J. The origins of the Ross operation. Images Paediatr Cardiol. 2012;14(2):3-5.
[6] VAN HOOF L, VERBRUGGHE P, JONES E AV, et al. Understanding Pulmonary Autograft Remodeling After the Ross Procedure: Stick to the Facts. Front Cardiovasc Med. 2022;9:829120.
[7] MAZINE A, EL-HAMAMSY I, VERMA S, et al. Ross Procedure in Adults for Cardiologists and Cardiac Surgeons: JACC State-of-the-Art Review.J Am Coll Cardiol. 2018;72(22):2761-2777.
[8] RYAN WH, SQUIERS JJ, HARRINGTON KB, et al. Long-term outcomes of the Ross procedure in adults. Ann Cardiothorac Surg. 2021;10(4):499-508.
[9] STARNES VA, BOWDISH ME, COHEN RG, et al. The Ross procedure utilizing the pulmonary autograft inclusion technique in adults. JTCVS Tech. 2021;10:372-376.
[10] LUCIANI GB, FAVARO A, CASALI G, et al. Ross operation in the young: a ten-year experience. Ann Thorac Surg. 2005;80(6):2271-2277.
[11] HAGE A, HAGE F, VALDIS M, et al. The Ross procedure is the optimal solution for young adults with unrepairable aortic valve disease. Ann Cardiothorac Surg. 2021;10(4):454-462.
[12] LISY M, KALENDER G, SCHENKE-LAYLAND K, et al. Allograft Heart Valves: Current Aspects and Future Applications. Biopreserv Biobank. 2017; 15(2):148-157.
[13] RODRIGUEZ-GABELLA T, VOISINE P, PURI R, et al. Aortic Bioprosthetic Valve Durability: Incidence, Mechanisms, Predictors, and Management of Surgical and Transcatheter Valve Degeneration. J Am Coll Cardiol. 2017;70(8):1013-1028.
[14] DALGLIESH AJ, PARVIZI M, LOPERA-HIGUITA M, et al. Graft-specific immune tolerance is determined by residual antigenicity of xenogeneic extracellular matrix scaffolds. Acta Biomater. 2018;79:253-264.
[15] HRYHOROWICZ M, ZEYLAND J, SLOMSKI R, et al. Genetically Modified Pigs as Organ Donors for Xenotransplantation. Mol Biotechnol. 2017; 59(9-10):435-444.
[16] RAHMANI B, MCGREGOR C, BYRNE G, et al. A Durable Porcine Pericardial Surgical Bioprosthetic Heart Valve: a Proof of Concept. J Cardiovasc Transl Res. 2019;12(4):331-337.
[17] MANJI RA, EKSER B, MENKIS AH, et al. Bioprosthetic heart valves of the future. Xenotransplantation. 2014;21(1):1-10.
[18] JIN C, CHERIAN RM, LIU J, et al. Identification by mass spectrometry and immunoblotting of xenogeneic antigens in the N- and O-glycomes of porcine, bovine and equine heart tissues. Glycoconj J. 2020;37(4):485-498.
[19] LUTZ AJ, LI P, ESTRADA JL, et al. Double knockout pigs deficient in N-glycolylneuraminic acid and galactose alpha-1,3-galactose reduce the humoral barrier to xenotransplantation. Xenotransplantation. 2013;20(1):27-35.
[20] SENAGE T, PAUL A, LE TOURNEAU T, et al. The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration. Nat Med. 2022;28(2):283-294.
[21] COCCIOLONE AJ, HAWES JZ, STAICULESCU MC, et al. Elastin, arterial mechanics, and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2018;315(2):H189-H205.
[22] WAHART A, HOCINE T, ALBRECHT C, et al. Role of elastin peptides and elastin receptor complex in metabolic and cardiovascular diseases. FEBS J. 2019;286(15):2980-2993.
[23] LIU J, LI B, JING H, et al. Swim Bladder as a Novel Biomaterial for Cardiovascular Materials with Anti-Calcification Properties. Adv Healthc Mater. 2020;9(2):e1901154.
[24] LI N, LI X, MA Y, et al. Swim bladder as an alternative biomaterial for bioprosthetic valves. Biomater Sci. 2021;9(24):8356-8365.
[25] MEEZAN E, HJELLE JT, BRENDEL K, et al. A simple, versatile, nondisruptive method for the isolation of morphologically and chemically pure basement membranes from several tissues. Life Sci. 1975;17(11):1721-1732.
[26] CRAPO PM, GILBERT TW, BADYLAK SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011;32(12):3233-3243.
[27] TAGHIZADEH B, GHAVAMI L, DERAKHSHANKHAH H, et al. Biomaterials in Valvular Heart Diseases. Front Bioeng Biotechnol. 2020;8:529244.
[28] WALETZKO J, DAU M, SEYFARTH A, et al. Devitalizing Effect of High Hydrostatic Pressure on Human Cells-Influence on Cell Death in Osteoblasts and Chondrocytes. Int J Mol Sci. 2020;21(11):3836.
[29] NASO F, GANDAGLIA A. Different approaches to heart valve decellularization: A comprehensive overview of the past 30 years. Xenotransplantation. 2018;25(1). doi: 10.1111/xen.12354.
[30] ROTHRAUFF BB, TUAN RS. Decellularized bone extracellular matrix in skeletal tissue engineering. Biochem Soc Trans. 2020;48(3):755-764.
[31] LIU X, CAI Y, XIA C, et al. An innovative method to obtain porous porcine aorta scaffolds for tissue engineering. Artif Organs. 2019;43(12):1162-1169.
[32] RAMM R, GOECKE T, THEODORIDIS K, et al. Decellularization combined with enzymatic removal of N‐linked glycans and residual DNA reduces inflammatory response and improves performance of porcine xenogeneic pulmonary heart valves in an ovine in vivo model. Xenotransplantation. 2020;27(2):e12571.
[33] GIL-RAMíREZ A, ROSMARK O, SPéGEL P, et al. Pressurized carbon dioxide as a potential tool for decellularization of pulmonary arteries for transplant purposes. Sci Rep. 2020;10(1):4031.
[34] TRANTINA-YATES AE, HUMAN P, ZILLA P. Detoxification on top of enhanced, diamine-extended glutaraldehyde fixation significantly reduces bioprosthetic root calcification in the sheep model. J Heart Valve Dis. 2003;12(1):93-100; discussion -1.
[35] FLAMENG W, HERMANS H, VERBEKEN E, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149(1):340-345.
[36] SHANG H, CLAESSENS SM, TIAN B, et al. Aldehyde reduction in a novel pericardial tissue reduces calcification using rabbit intramuscular model. J Mater Sci Mater Med. 2017;28(1):16.
[37] XI T, MA J, TIAN W, et al. Prevention of tissue calcification on bioprosthetic heart valve by using epoxy compounds: a study of calcification tests in vitro and in vivo. J Biomed Mater Res. 1992;26(9): 1241-1251.
[38] LI J, REN N, QIU J, et al. Carbodiimide crosslinked collagen from porcine dermal matrix for high-strength tissue engineering scaffold. Int J Biol Macromol. 2013;61:69-74.
[39] ZEEMAN R, DIJKSTRA PJ, VAN WACHEM PB, et al. Successive epoxy and carbodiimide cross-linking of dermal sheep collagen. Biomaterials. 1999;20(10):921-931.
[40] EVERAERTS F, TORRIANNI M, HENDRIKS M, et al. Biomechanical properties of carbodiimide crosslinked collagen: influence of the formation of ester crosslinks. J Biomed Mater Res A. 2008;85(2):547-555.
[41] LEI Y, JIN W, LUO R, et al. Bioprosthetic heart valves’ structural integrity improvement through exogenous amino donor treatments. J Mater Res. 2018;33(17):2576-2585.
[42] LIM HG, KIM SH, CHOI SY, et al. Anticalcification effects of decellularization, solvent, and detoxification treatment for genipin and glutaraldehyde fixation of bovine pericardium. Eur J Cardiothorac Surg. 2012;41(2):383-390.
[43] CHANG Y, TSAI CC, LIANG HC, et al. In vivo evaluation of cellular and acellular bovine pericardia fixed with a naturally occurring crosslinking agent (genipin). Biomaterials. 2002;23(12):2447-2457.
[44] 郑剑莹. EDC和京尼平交联对壳聚糖/硅酸钙/丝素蛋白支架影响的研究[D].长春:吉林大学,2021.
[45] 张佳颖,索海瑞,徐铭恩,等.京尼平交联3D打印胶原/壳聚糖支架的表征[J].中国组织工程研究,2022,26(28):4477-4482.
[46] LIU J, LI B, JING H, et al. Curcumin-crosslinked acellular bovine pericardium for the application of calcification inhibition heart valves. Biomed Mater. 2020;15(4):045002.
[47] FANG G, CHEN S, HUANG Q, et al. Curcumin suppresses cardiac fibroblasts activities by regulating the proliferation and cell cycle via the inhibition of the p38 MAPK/ERK signaling pathway. Mol Med Rep, 2018;18(2):1433-1438.
[48] CIFTCI O, TURKMEN NB, TASLIDERE A. Curcumin protects heart tissue against irinotecan-induced damage in terms of cytokine level alterations, oxidative stress, and histological damage in rats. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(8):783-791.
[49] BALALAIE A, REZVANI MB, MOHAMMADI BASIR M. Dual function of proanthocyanidins as both MMP inhibitor and crosslinker in dentin biomodification: A literature review. Dent Mater J. 2017;37(2):173-182.
[50] SIMIONESCU A, SIMIONESCU DT, DEAC RFP. Matrix metalloproteinases in the pathology of natural and bioprosthetic cardiac valves. Cardiovasc Pathol. 1996;5(6):323-332.
[51] TANIMURA S, KADOMOTO R, TANAKA T, et al. Suppression of tumor cell invasiveness by hydrolyzable tannins (plant polyphenols) via the inhibition of matrix metalloproteinase-2/-9 activity. Biochem Biophys Res Commun. 2005;330(4):1306-1313.
[52] ISENBURG JC, SIMIONESCU DT, VYAVAHARE NR. Tannic acid treatment enhances biostability and reduces calcification of glutaraldehyde fixed aortic wall. Biomaterials. 2005;26(11):1237-1245.
[53] 刘其静.单宁酸鞣制对牛心包材料的改性研究[D].武汉:华中农业大学,2019.
[54] 易亮,宋明哲,吴忠仕,等.一种复合交联生物瓣膜及其制备方法, CN113425910A[P/OL].
[55] GHOUAS H, HADDOU B, KAMECHE M, et al. Removal of Tannic Acid From Aqueous Solution by Cloud Point Extraction and Investigation of Surfactant Regeneration by Microemulsion Extraction. J Surfact Deterg. 2015;19. doi: 10.1007/s11743-015-1764-9
[56] 王云兵,雷洋,訾振军.一种采用酶交联和茶多酚组合联用处理生物瓣膜的方法, CN110841110B [P/OL].
[57] BARTOLI-LEONARD F, AIKAWA E. Heart Valve Disease: Challenges and New Opportunities. Front Cardiovasc Med. 2020;7:602271.
[58] KOSTYUNIN AE, YUZHALIN AE, REZVOVA MA, et al. Degeneration of Bioprosthetic Heart Valves: Update 2020. J Am Heart Assoc. 2020; 9(19):e018506.
[59] LYU N, DU Z, QIU H, et al. Mimicking the Nitric Oxide-Releasing and Glycocalyx Functions of Endothelium on Vascular Stent Surfaces. Adv Sci (Weinh). 2020;7(21):2002330.
[60] GULDNER NW, JASMUND I, ZIMMERMANN H, et al. Detoxification and endothelialization of glutaraldehyde-fixed bovine pericardium with titanium coating: a new technology for cardiovascular tissue engineering. Circulation. 2009;119(12):1653-1660.
[61] ASSMANN A, DELFS C, MUNAKATA H, et al. Acceleration of autologous in vivo recellularization of decellularized aortic conduits by fibronectin surface coating. Biomaterials. 2013;34(25):6015-6026.
[62] MARINVAL N, MORENC M, LABOUR MN, et al. Fucoidan/VEGF-based surface modification of decellularized pulmonary heart valve improves the antithrombotic and re-endothelialization potential of bioprostheses. Biomaterials. 2018;172:14-29.
[63] YE X, HU X, WANG H, et al. Polyelectrolyte multilayer film on decellularized porcine aortic valve can reduce the adhesion of blood cells without affecting the growth of human circulating progenitor cells. Acta Biomater. 2012;8(3):1057-1067.
[64] CHENG S, LIU X, QIAN Y, et al. Double-Network Hydrogel Armored Decellularized Porcine Pericardium as Durable Bioprosthetic Heart Valves. Adv Healthc Mater. 2022;11(8):e2102059.
[65] WANG Y, MA B, LIU K, et al. A multi-in-one strategy with glucose-triggered long-term antithrombogenicity and sequentially enhanced endothelialization for biological valve leaflets. Biomaterials. 2021;275: 120981.
[66] FANG C, DENG Z, CAO G, et al. Co–Ferrocene MOF/Glucose Oxidase as Cascade Nanozyme for Effective Tumor Therapy. Adv Funct Mater. 2020;30(16):1910085.
[67] SOLOMONICA A, CHOUDHURY T, BAGUR R. Newer-generation of Edwards transcatheter aortic valve systems: SAPIEN 3, Centera, and SAPIEN 3 Ultra. Expert Rev Med Devices. 2019;16(2):81-87.
[68] SCHäFER U, SCHIRMER J, SCHOFER N, et al. First in human implantation of a novel transfemoral self-expanding transcatheter heart valve to treat pure aortic regurgitation. EuroIntervention. 2017;13(11):1296-1299.
[69] NISHIMURA RA, OTTO CM, BONOW RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014;148(1): e1-e132.
[70] WANG S, MENG X, LUO Z, et al. Transapical Beating-Heart Mitral Valve Repair Using a Novel Neochord Implantation System. Ann Thorac Surg. 2018;106(5):e265-e267.
[71] 蒲朝霞,刘先宝,林心平,等.经食管超声心动图引导DragonFly系统缘对缘修复治疗三尖瓣反流的初步经验[J].中华超声影像学杂志,2021,30(10):843-847.
[72] LU FL, YE MM, ZHAO AM, et al. First-in-Man Experience of Transcatheter Tricuspid Valve Replacement With LuX-Valve in High-Risk Tricuspid Regurgitation Patients. JACC Cardiovasc Interv. 2020;13(13):1614-1616.
[73] 陈思,顾君君,杨帆,等.LuX-Valve系统经导管三尖瓣置换26例近期疗效分析[J].中国心血管病研究,2022,20(2):104-107.
[74] BLACKMAN DJ, SARAF S, MACCARTHY PA, et al. Long-Term Durability of Transcatheter Aortic Valve Prostheses. J Am Coll Cardiol. 2019;73(5): 537-545.
[75] DURAND E, SOKOLOFF A, URENA-ALCAZAR M, et al. Assessment of Long-Term Structural Deterioration of Transcatheter Aortic Bioprosthetic Valves Using the New European Definition. Circ Cardiovasc Interv. 2019;12(4):e007597.
[76] SAWAYA F, JORGENSEN TH, SONDERGAARD L, et al. Transcatheter Bioprosthetic Aortic Valve Dysfunction: What We Know So Far. Front Cardiovasc Med. 2019;6:145.
[77] 林振乾,黄琼,黄海伦,等.经导管主动脉瓣置换术并发症的研究进展[J].中国心血管病研究,2021,19(11):1000-1005.
[78] KOLTE D, VLAHAKES GJ, PALACIOS IF, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients. J Am Coll Cardiol. 2019; 74(12):1532-1540.
[79] THOURANI VH, EDELMAN JJ, MEDURI CU. TAVR in TAVR. J Am Coll Cardiol. 2020;75(16):1894-1896.
|